A Phase 2 interventional study of Botulinum toxin A ( BoNT-A) and Hyaluronic acid (HA) in Painful Unilateral Femorotibial Knee Osteoarthritis of Any Etiology, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.
Sponsored by University Hospital, Strasbourg, France · Phase 2, Interventional, and Treatment
In France, osteoarthritis affects about 10 million people and knee osteoarthritis represents 35% of cases. It is thought that more than 2.5 million people older than 65 years have knee osteoarthritis.
Currently, osteoarthritis management is based on three major axes:
Intra-articular pharmacological treatments:
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 50 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Clinical:
Drug: Botulinum toxin A ( BoNT-A)
Device: Hyaluronic acid (HA)
Intra-articular injection of BoNT-A
Intra-articular injection of Hyaluronic acid
Evaluation of pain measured using the WOMAC pain sub-score
Time frame: Change from baseline WOMAC pain sub-score at 3 months
Evaluation of the antalgic effect of BoNT-A vs hyaluronic acid measured using a verbal rating scale (VRS)
Time frame: 1 week after injection
Evaluation of the patients' functional improvement based on the WOMAC score ("stiffness and function sub-score" and total score)
Time frame: Before injection, 1 month, 3 months and 6 months following injection
Evaluation of the patients' functional improvement using the Timed Up-and-go Test
Time frame: Before injection, 1 month, 3 months and 6 months following injection
Evaluation of the quality of life based on the SF-36 score
Time frame: Before injection, 1 month, 3 months and 6 months following injection
Frequency, seriousness and severity of adverse event reactions
Time frame: during the 6 months following injection
Changes in pain treatment score (using a correspondence table)
Time frame: Change from baseline pain treatment score at 6 months
Changes in muscular strenght et muscular trophicity (using dynanometer and measure of knee and thin circumference)
Time frame: Before injection, 1 month, 3 months and 6 months following injection
Changes in passive and active articular knee amplitude, by goniometry
Time frame: Before injection, 1 month, 3 months and 6 months following injection
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France